CTLT Catalent
- 55.250
- -0.360-0.65%
- 55.640
- +0.390+0.71%
Catalent News
Argus Downgrades Catalent to Sell From Buy
Catalent (CTLT) has an average hold rating and a price target range of $46 to $63.50, according to analysts polled by Capital IQ. Price: 55.42, Change: -0.19, Percent Change: -0.34
Unusual Options Activity: PBR, GME and Others Attract Market Bets, PBR V/OI Ratio Reaches 312.5
EST May 15th Afternoon Delivery - In the last two hours of trading, 5 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends
Novo Nordisk will sell four types of Eurobonds to finance the acquisition of Catalent's plant
Gronghui, May 14 | People familiar with the matter revealed that on Tuesday, several banks will sell Euro-denominated bonds with 4 maturities on behalf of Novo Nordisk through Novo Nordisk's financial subsidiary in the Netherlands, with terms ranging from 2 to 10 years. Novo Nordisk issued bonds for the first time in more than two years to fund plans to increase production of its major drug. A Novo Nordisk spokesperson said the proceeds will be used to help the Danish pharmaceutical giant buy the Catalent plant for $11 billion. According to reports, the company is investing heavily to expand its production capacity, and announced plans to acquire three plants originally owned by Catalent earlier this year
Update: Market Chatter: Novo Nordisk Taps Banks for Potential Bond Issue
(Updates to add Novo Nordisk's response) Novo Nordisk (NOVO-B.CO) hired banks for the potential issue of euro-nominated bonds to fund general corporate purposes, including funding its $16.5 billion ac
Form 144 | Catalent(CTLT.US) Insider Proposes to Sell 176.62K in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Catalent(CTLT.US)$ Insider Crane Rosemary A intends to sell 3,167 shares of its common stock on May 13, with a total market value of approximately $176.62K. Crane Ro
Market Chatter: Novo Nordisk Taps Banks for Potential Bond Issue
Novo Nordisk (NOVO-B.CO) hired banks for the potential issue of euro-nominated bonds to fund general corporate purposes, including funding its $16.5 billion acquisition of US-based Catalent. Bloomberg
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
Catalent's Merger Deal With Novo Holdings: A Tightrope Walk Amidst Restrictive Clauses and Hefty Termination Fees
Catalent's Resilient Growth and Positive Outlook Reinforce Buy Rating
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
Catalent, Inc. CTLT reported third-quarter fiscal 2024 adjusted loss per share of 6 cents, which was narrower than the year-ago period’s loss per share of 9 cents.
RBC Capital Sticks to Their Hold Rating for Catalent (CTLT)
RBC Capital analyst Sean Dodge maintained a Hold rating on Catalent (CTLT) yesterday and set a price target of $63.50.
Decoding Catalent Inc (CTLT): A Strategic SWOT Insight
On May 8, 2024, Catalent Inc (NYSE:CTLT), a leading contract development and manufacturing organization (CDMO), filed its 10-Q report, offering a glimpse into its financial health and operational performance.
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
Catalent (CTLT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.24.
Catalent Q3 EPS $(0.06) Misses $0.21 Estimate, Sales $1.07B Miss $1.12B Estimate
Catalent (NYSE:CTLT) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.21 by 128.57 percent. This is a 33.33 percent increase over losses of $(0.09) per
Research Alert: CFRA Keeps Hold Opinion On Shares Of Catalent, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We reduce our target to $59 from $60, 34
Earnings Flash (CTLT) CATALENT Posts Q3 Revenue $1.07B
04:35 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (CTLT) CATALENT Posts Q3 Revenue $1.07B
Catalent | 10-Q: Quarterly report
Press Release: Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results -- Q3'24 net revenue of $1.07 billion increased 4% as reported, or 3% in constant currency(1), compared to Q3'23. -- Q3'24 net r
Catalent 3Q Loss/Shr 56c >CTLT
Catalent 3Q Loss/Shr 56c >CTLT
Siren Biotechnology And Catalent Partner To Manufacture AAV Gene Therapies For Cancer
Siren Biotechnology And Catalent Partner To Manufacture AAV Gene Therapies For Cancer
Analysis
Price Target
No Data
